Pacific Biosciences 株価情報 (NASDAQ: PACB)

最新ニュース Pacific Biosciences (NASDAQ:PACB) 株価情報

Pacific Biosciences

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences of California Inc

PacBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), a leader in high-quality, long-read sequencing, is proud to announce its critical role in a study to be published in Nature Genetics. The study, titled&nbsp;Synchronized long-read genome, methylome, epigenome, and transcriptome for resolving a Mendelian condition, showcases how researchers leveraged PacBio's advanced sequencing solutions, including the synchronized Fiber-seq and Kinnex (formerly MAS-seq) multiomic approach, to uncover the genetic and molecular basis of a rare and complex Mendelian condition.
In collaboration with the University of Washington and the Undiagnosed Diseases Network (UDN), the study applied PacBio's state-of-the-art Revio&#x2122; sequencing system to integrate long-read genomic, transcriptomic, methylomic, and epigenomic data in a synchronized analysis to analyze a 9-month-old patient with an unsolved condition involving bilateral retinoblastomas, developmental delays, and additional symptoms. Previous diagnostic methods, including short-read sequencing, were unable to provide an answer. With PacBio's innovative multiomic solutions, researchers identified a chromosome X;13 balanced translocation disrupting four key genes—each through a unique molecular mechanism.

Biotech

News

General

PACB

PacBio Announces Publication In Nature Genetics Study Using Advanced Sequencing To Uncover Genetic Basis Of Rare Mendelian Condition In 9-Month-Old Patient

Across the recent three months, 4 analysts have shared their insights on Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $3.06, a high estimate of $6.00, and a low estimate of $1.75. This current average has decreased by 18.4% from the previous average price target of $3.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1737669645_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Pacific Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.75</td>
<td>$2.25</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$2.00</td>
<td>-</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$2.50</td>
<td>$2.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pacific Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacific Biosciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Pacific Biosciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Pacific Biosciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PACB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacific Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Pacific Biosciences: A Closer Look</h2>
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
<h3>Financial Milestones: Pacific Biosciences's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining Pacific Biosciences's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -28.23% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacific Biosciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -151.94% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Pacific Biosciences's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -12.84%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Pacific Biosciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.1%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Pacific Biosciences's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.03, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What Analysts Are Saying About Pacific Biosciences Stock

WIIM

Pacific Biosciences of California shares are trading lower after Goldman Sachs cut its price target on the stock from $2.25 to $1.75.

Goldman Sachs analyst Matthew Sykes maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Neutral and lowers the price target from $2.25 to $1.75.

Price Target

Goldman Sachs Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.75

Pacific Biosciences shares are trading lower after the company issued worse-than-expected preliminary Q4 revenue.

PacBio And Radboud UMC Published Study In American Journal Of Human Genetics

Guidance

Pacific Biosciences Sees Prelim. Q4 Revenue ~$39.2M Vs $40.536M Est.

PacBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human gut health test powered by Intus Bio's groundbreaking Titan-1 platform and PacBio's HiFi sequencing technology. By combining Intus Bio's patented strain-level resolution assay and AI-powered analysis with PacBio's renowned sequencing accuracy, GutID sets a new benchmark in gut microbiome testing, and is the only comprehensive and accurate gut microbiome test available today.

PacBio and Intus Bio Launch GutID: First AI-Powered, HiFi Sequencing Gut Microbiome Test

PacBio Ships First Vega Systems To Berry Genomics For Clinical Assay Development In Asian Markets, With Plans For NMPA Regulatory Approval And Over 50 Additional Units Committed

Ark Invest CEO Cathie Wood is doubling <a href="https://www.benzinga.com/general/biotech">down on genomics</a>.
What Happened: Pacific Biosciences of California Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), known as PacBio, is biotech&#8217;s new kid on the block. The company's Vega sequencer might be the spark that reignites the genomics flame in Ark Invest's portfolios.
ARK Invest has been consistently <a href="https://cathiesark.com/arkk/trades">increasing</a> its stake in PacBio since mid-November. Most recently, the fund added over 24,000 shares on Dec. 3. 
While the stock is down 75% over the past year, Ark's conviction shows no signs of wavering. Wood believes in the sector's long-term growth potential, particularly with genomics merging with AI advancements.
During eToro's &#8220;Digest &amp; Invest&#8221; podcast, Woods emphasized that investors need to look beyond conventional benchmarks. She noted that declining AI training costs enable breakthroughs in gene editing and genome sequencing.
Despite market headwinds like high interest rates, Wood remains bullish, suggesting those ignoring the genomics sector risk missing out on transformative opportunities.
Read Also: <a href="https://www.benzinga.com/news/24/12/42292280/why-purple-biotech-ppbt-stock-is-getting-hammered">Why Purple Biotech (PPBT) Stock Is Getting Hammered</a>
Why It Matters: PacBio carved out its niche in long-read sequencing, an advanced technology that maps entire genomes with unparalleled accuracy. 
The Menlo Park, California-based company's latest launch, the Vega benchtop sequencer, combines affordability ($169,000) with precision. It aims to democratize access to PacBio's HiFi sequencing tech.
PacBio has steadily enhanced its technology, incorporating Sequencing by Binding (SBB) chemistry after acquiring Omniome in 2021. The result? A unique offering that bridges short-read and long-read sequencing needs.
Financially, PacBio is tightening its belt. Non-GAAP operating expenses dropped to $62.4 million in the third quarter 2024, down from $90.9 million a year ago. Meanwhile, consumables sales hit $18.5 million, marking a record for the company's Onso system.
PacBio's story isn't without challenges, considering short interest is over 20%. Yet Wood's Ark holds a 12.26% stake (as of Sept. 30), solidifying her vote of confidence in PacBio.
Biotech's broader market surged by over 29% this year. PacBio&#8217;s shares have struggled, but Wood's accumulation suggests she sees this as a buying opportunity rather than a red flag.
What&#8217;s Next: Vega's launch is slated for early 2025.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/42243781/viking-therapeutics-stock-on-brink-of-death-cross-as-weight-loss-hype-loses-momentum">Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum</a></li>
</ul>
Image: Courtesy of Cathie Wood

Long Ideas

Health Care

Tech

Trading Ideas

Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$9.00</td>
<td>$107.2K</td>
<td>9.1K</td>
<td>2.4K</td>
</tr>
<tr>
<td>SRRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$40.00</td>
<td>$29.6K</td>
<td>4.6K</td>
<td>1.1K</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$575.00</td>
<td>$36.0K</td>
<td>57</td>
<td>518</td>
</tr>
<tr>
<td>PACB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$5.00</td>
<td>$25.2K</td>
<td>668</td>
<td>405</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$33.00</td>
<td>$31.1K</td>
<td>630</td>
<td>367</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$112.00</td>
<td>$68.8K</td>
<td>260</td>
<td>188</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$960.00</td>
<td>$66.1K</td>
<td>1.8K</td>
<td>177</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$32.50</td>
<td>$37.7K</td>
<td>4.0K</td>
<td>51</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$500.00</td>
<td>$28.0K</td>
<td>103</td>
<td>35</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$60.00</td>
<td>$68.4K</td>
<td>292</td>
<td>12</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we notice a call option trade that happens to be bearish, expiring in 44 day(s) on January 17, 2025. This event was a transfer of 1650 contract(s) at a $9.00 strike. The total cost received by the writing party (or parties) was $107.2K, with a price of $65.0 per contract. There were 9105 open contracts at this strike prior to today, and today 2455 contract(s) were bought and sold. 
• For SRRK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>), we notice a call option sweep that happens to be bullish, expiring in 44 day(s) on January 17, 2025. This event was a transfer of 76 contract(s) at a $40.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $29.6K, with a price of $390.0 per contract. There were 4683 open contracts at this strike prior to today, and today 1199 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option trade with bearish sentiment. It expires in 16 day(s) on December 20, 2024. Parties traded 200 contract(s) at a $575.00 strike. The total cost received by the writing party (or parties) was $36.0K, with a price of $180.0 per contract. There were 57 open contracts at this strike prior to today, and today 518 contract(s) were bought and sold. 
• For PACB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), we notice a call option trade that happens to be bullish, expiring in 772 day(s) on January 15, 2027. This event was a transfer of 389 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $25.2K, with a price of $65.0 per contract. There were 668 open contracts at this strike prior to today, and today 405 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be bearish, expiring in 79 day(s) on February 21, 2025. This event was a transfer of 62 contract(s) at a $33.00 strike. The total cost received by the writing party (or parties) was $31.1K, with a price of $502.0 per contract. There were 630 open contracts at this strike prior to today, and today 367 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be bullish, expiring in 9 day(s) on December 13, 2024. This event was a transfer of 166 contract(s) at a $112.00 strike. This particular call needed to be split into 37 different trades to become filled. The total cost received by the writing party (or parties) was $68.8K, with a price of $415.0 per contract. There were 260 open contracts at this strike prior to today, and today 188 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bearish sentiment. It expires in 107 day(s) on March 21, 2025. Parties traded 29 contract(s) at a $960.00 strike. The total cost received by the writing party (or parties) was $66.1K, with a price of $2280.0 per contract. There were 1883 open contracts at this strike prior to today, and today 177 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a put option sweep that happens to be bearish, expiring in 107 day(s) on March 21, 2025. This event was a transfer of 51 contract(s) at a $32.50 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $37.7K, with a price of $740.0 per contract. There were 4013 open contracts at this strike prior to today, and today 51 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option trade with bearish sentiment. It expires in 134 day(s) on April 17, 2025. Parties traded 10 contract(s) at a $500.00 strike. The total cost received by the writing party (or parties) was $28.0K, with a price of $2800.0 per contract. There were 103 open contracts at this strike prior to today, and today 35 contract(s) were bought and sold. 
• For SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we notice a put option trade that happens to be bearish, expiring in 16 day(s) on December 20, 2024. This event was a transfer of 12 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $68.4K, with a price of $5704.0 per contract. There were 292 open contracts at this strike prior to today, and today 12 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

RXRX

SAVA

SRRK

VRTX

10 Health Care Stocks Whale Activity In Today's Session

UBS analyst John Sourbeer downgrades Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) from Buy to Neutral and announces $2 price target.

Downgrades

UBS Downgrades Pacific Biosciences to Neutral, Announces $2 Price Target

Scotiabank analyst Sung Ji Nam maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Sector Outperform and lowers the price target from $7 to $6.

Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $6

Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Neutral and raises the price target from $2 to $2.5.

Piper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2.5

U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.2% on Friday.
Shares of Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/SG/earnings">quarterly financial results</a>.
Sweetgreen reported a quarterly loss of 18 cents per share, compared to market expectations for a loss of 16 cents per share. The company reported quarterly sales of $173.400 million which missed the analyst consensus estimate of $175.533 million.
Sweetgreen shares dipped 15% to $35.87 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) shares fell 33.6% to $16.31 in pre-market trading after the company reported worse-than-expected third-quarter financial results.</li>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares fell 29% to $1.98 in pre-market trading after the company reported worse-than-expected quarterly revenue results.</li>
<li>Maravai LifeSciences Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) declined 26.6% to $5.75 in pre-market trading after the company reported worse-than-expected third-quarter financial results and cut its FY24 sales guidance.</li>
<li>Redfin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>) fell 14.1% to $9.85 in pre-market trading after the company reported worse-than-expected third-quarter financial results.</li>
<li>Pinterest, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) shares dipped 12.7% to $29.62 in pre-market trading after the company reported worse-than-expected third-quarter EPS results.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) dipped 12.6% to $2.14 in pre-market trading after the company reported worse-than-expected third-quarter revenue results.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) declined 9.7% to $119.62 in pre-market trading following third-quarter results.</li>
<li>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) fell 5.2% to $36.97 in pre-market trading after the company reported worse-than-expected third-quarter revenue results and lowered its FY24 revenue guidance..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

DKNG

MRVI

PINS

RDFN

Sweetgreen Posts Downbeat Results, Joins Evolent Health, Redfin, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Pacific Biosciences shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Pacific Biosciences Says On The Path To Return To Growth In 2025 And Beyond

Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 37.04 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $39.97 million which missed the analyst consensus estimate of $41.95 million by 4.74 percent. This is a 28.23 percent decrease over sales of $55.69 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Pacific Biosciences Q3 2024 Adj EPS $(0.17) Beats $(0.22) Estimate, Sales $39.97M Miss $41.95M Estimate

Reported Earlier, PacBio's Vega System Expands Accessibility To HiFi Sequencing, Transforming Benchtop Research

PacBio shares are trading higher after the company announced SPRQ sequencing chemistry for its Revio sequencing systems.

PacBio announces preliminary Q4 revenue of $39.2M

PacBio (PACB) announced a significant publication from Radboud University Medical Center and its research partners in the American Journal of Human...

PacBio, Radboud UMC announces study results using HiFi long read sequencing

The company also announced preliminary unaudited revenue for the full year 2024 of $154M. "Though challenging, 2024 was a productive year for PacBi...

PacBio reports Q4 preliminary revenue $39.2M, consensus $40.63M

In a report released today, Luke Sergott from Barclays maintained a Hold rating on Pacific Biosciences (PACB – Research Report), with a price targe...

Barclays Reaffirms Their Hold Rating on Pacific Biosciences (PACB)

PacBio (PACB) announced the Global Institute for Food Security, GIFS, at the University of Saskatchewan, USask, as the first Revio PacBio Certified...

PacBio announces GIFS at USask as first Revio PacBio CSP in Canada

Life sciences stocks fall on NIH funding concerns

Latest data shows the largest indicative borrow rate increases among liquid option names include: Candel Therapeutics Inc (CADL) 58.95% +44.69, Pac...

Largest borrow rate increases among liquid names

PacBio (PACB) announces its critical role in a study to be published in Nature Genetics. The study, titled Synchronized long-read genome, methylome...

PacBio announces role in study to be published in Nature Genetics

Pacific Biosciences ( ($PACB) ) has shared an update. On January 30, 2025, PacBio appointed Christopher M. Smith, CEO of NeoGenomics, to its Board ...

Pacific Biosciences Announces Board Changes for Strategic Growth

PacBio (PACB) announced the appointment of Chris Smith to its Board of Directors, effective today. Smith is currently the Chief Executive Officer o...

PacBio appoints Smith to board of directors

AISP

BRKR

CADL

HOLO

ILMN

JMIA

MRKR

OPFI

QGEN

RVTY

SMLR

Press Releases

PacBio to Present at Upcoming Investor Conferences

PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference

PacBio Announces Shipment of Vega Systems to Berry Genomics to Support its Clinical Assay Development for Asian Markets

PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing

PacBio Announces Preliminary Fourth Quarter and Full Year Revenue

PacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease Diagnostics

PacBio Names Global Institute for Food Security as Canada's First Revio Certified Service Provider

PacBio Technology Powers Landmark Multiomic Study Published in Nature Genetics

Management

PacBio Announces Appointment of Chris Smith to Board of Directors

PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Akoya Biosciences

Atlantic International Corp. - Common Stock

Atlantic International

BioLife Solns

ChromaDex

Codexis

Champions Oncology

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Pacific Biosciences

ニュース

最新ニュース Pacific Biosciences (NASDAQ:PACB) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル